Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update

November 3, 2023

Received two grant awards from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health

LOS GATOS, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) — Aridis Pharmaceuticals, Inc. (OTCQB:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its third quarter ended September 30, 2023.

Read more at globenewswire.com

Related news for (ARDS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.